Compare BORR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | MRVI |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | BORR | MRVI |
|---|---|---|
| Price | $4.07 | $8.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $4.88 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 9.0M | 2.2M |
| Earning Date | 11-18-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $14.01 |
| Revenue Next Year | $20.61 | $6.20 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.89 | $2.55 |
| 52 Week High | $6.66 | $9.42 |
| Indicator | BORR | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 60.70 |
| Support Level | $3.95 | $5.54 |
| Resistance Level | $4.56 | $8.74 |
| Average True Range (ATR) | 0.28 | 0.47 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 16.42 | 98.95 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.